Document:

edit_Ex10_12

		
			Exhibit 10.12
		

		
			
		

		
			July 19, 2016
		

		
			 
		

		
			Gerald F. Cox, M.D., Ph.D.
		

		
			Re:  Offer of Employment
		

		
			Dear Gerry,
		

		
			On behalf of Editas Medicine, Inc. (the “Company”), I am pleased to offer you employment with the Company.  The purpose of this letter is to set forth the terms of your employment with the Company, should you accept our offer.
		

		
			I am pleased to offer you the position of Chief Medical Officer at the Company, reporting to the Chief Executive Officer.
		

		
			Your base salary will be at the rate of $16,666.67 per semi-monthly pay period (equivalent to an annualized base salary of $400,000.00).  You will be employed on a full-time basis.  Following commencement of your employment with the Company, you will be entitled to continue your ongoing work at Boston Children’s Hospital on a schedule and frequency consistent with your current schedule (which is generally 0.5 days per week), provided that such activity does not interfere or conflict with your obligations to the Company (as reasonably determined by the Board of Directors of the Company).
		

		
			Additionally, you will be eligible to receive an annual performance bonus, targeted at 35% of your annual base salary, to be determined based on the achievement of your individual goals and the Company’s goals during the applicable fiscal year, and on a pro-rated basis.  Such bonus shall be subject to the approval of the Company’s Board of Directors (or a committee thereof).
		

		
			You must be an active employee of the Company on the date any bonus is distributed in order to be eligible for and to earn a bonus award, as it also serves as an incentive to remain employed by the Company, provided that the Company will award and pay any bonus for the prior calendar year before March 15th of the next succeeding calendar year.  Your effective date of hire as an employee (the “Start Date”) is to be mutually agreed upon by you and the Company, but not later than October 3, 2016.
		

		
			Subject to approval of the Company’s Board of Directors, the Company will grant you a stock option to purchase an aggregate of 225,000 shares of the Company’s common stock (the “Option”) at an exercise or purchase price equal to the fair market value of the Company’s common stock on the date of grant.  The Option will vest over four (4) years at the rate of 25% on the first anniversary of the
		

		
			
		

		
			

		 

			

					

						Confidential

					

					

						1

				

		

			 

		

 

		

			

		

		

		
			commencement date of your employment, and an additional 2.0833% of the original number of shares at the end of each successive month following the first anniversary of the vesting commencement date until the fourth anniversary of the commencement date of your employment.  The Option grant will be brought to the Board of Directors for approval after you begin employment with the Company.  The Option will be evidenced in writing by, and subject to the terms of the 2015 Stock Incentive Plan (or such other plan, including an inducement plan or agreement, under which such option is granted) and a stock option agreement provided by the Company.
		

		
			You will be eligible to participate in the Company’s Severance Benefits Plan, a copy of which is available at https://www.see.gov/Archives/edgar/data/1650664/000104746916009534/a2226902zex_10_27.htm), at the Chief Medical Officer level.  Your eligibility under the Severance Benefits Plan is subject to the terms and conditions thereof.
		

		
			You will be eligible to participate in the Company’s Medical and Dental Insurance Programs, as well as all other Company benefits, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs.  The benefit programs made available by the Company, and the rules, terms and conditions for participation in such benefit plans, may be changed by the Company at any time, in its sole discretion or as otherwise  required by law, without advance notice.
		

		
			You will be eligible for a maximum of four weeks of vacation per calendar year to be taken at such times as may be approved by the Company.  The number of vacation days for which you are eligible shall accrue at the rate of 1.67 days per month that you are employed during such calendar year.  Additionally, you will receive l personal day and 11 paid holidays annually, in accordance with the Company holiday schedule.
		

		
			It is understood that you are an “at-will” employee.  You are not being offered employment for a definite period of time or pursuant to an employment contract, and either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause or prior notice and without additional compensation to you.
		

		
			Your normal place of work will be at the offices of the Company in Cambridge, Massachusetts.  Enclosed for your review is a Non-Solicitation, Non-Competition, Confidentiality and Assignment Agreement (the “Agreement”).  This offer of employment is conditioned on your willingness to sign and abide by the terms of the Agreement.  You will be expected to sign the Agreement on or prior to your Start Date.
		

		
			In making this offer, the Company understands, based on representations made by you, that you are not under any obligation to any former employer or any person or entity which would prevent, limit, or impair in any way your acceptance of this offer or employment or the performance by you of your duties as an employee of the Company. In accepting this offer you represent and warrant the foregoing to be true and correct and that in connection with providing services to the Company you will not (i) use any confidential and/or proprietary information of any third party, including, without limitation, any former employer, and (ii) bring any biological or other materials to the Company.
		

		
			The Immigration Reform and Control Act requires employers to verify the employment eligibility and identity of new employees.  You will be required to complete a Form I-9 which
		

		
			
		

		
			

		 

			

					

						Confidential

					

					

						2

				

		

			 

		

 

		

			

		

		

		
			will be provided to you before the Start Date.  Please bring the appropriate documents listed on that form with you when you report for work.  We will not be able to employ you if you fail to comply with this requirement.
		

		
			This letter agreement and the Agreement referenced above constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (formal or informal, whether written, oral or implied) between you and the Company.  This letter agreement may not be amended or modified except by an express written agreement signed by both you and a duly authorized officer of the Company, although your job duties, title, reporting relationship, compensation and benefits may change from time to time in the Company’s sole discretion and provided that the “at-will” nature of your employment may only be changed by a written agreement signed by you and the Chief Executive Officer, which expressly states the intention to modify the at-will nature of your employment.  Nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company, except to the extent you are eligible for post-employment benefits under the Severance Benefit Plan.
		

		
			As an employee of the Company, you will be required to familiarize yourself and comply with all Company policies and procedures.  Violations of the Company’s policies may lead to immediate termination of your employment.  Further, the Company’s premises, including all workspaces, furniture, documents and other tangible materials, together with all information technology resources of the Company (including computers, portable devices, data and other electronic files (whether in hard copy or electronic form), and all internet and email communications) are subject to oversight and inspection by the Company at any time.  Company employees shall have no expectation of privacy with regard to any Company premises, materials, resources or information.
		

		
			Please indicate your acceptance of this offer by signing and returning the enclosed copy of this letter no later than July 20, 2016.  You may indicate your acceptance of this offer by signing on the appropriate space below and returning a signed, scanned copy along with the other necessary agreements referenced in this letter to Katrine Bosley at ksb@editasmed.com or returning by mail to Editas Medicine, Inc., 300 Third Street, Cambridge, MA 02142, Attention: Katrine Bosley.  This offer will remain open until 5:00 p.m. on the 5th business day after your receipt of this offer.
		

		
			Please know that we are truly enthused at the prospect of you becoming part of the Editas team and at your leadership helping to build what we hope will be an exceptional organization, one that is both a scientific pioneer and that delivers transformative medicines to many, many patients.  We believe that you will be a fundamental part of turning that aspiration into reality.
		

			
					
						Very truly yours,

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						/s/ Katrine Bosley

					
					
						 

					
					
						 

				
	
					
						Katrine Bosley

					
					
						 

					
					
						 

				
	
					
						Chief Executive Officer

					
					
						 

					
					
						 

				
	
					
						Editas Medicine, Inc.

					
					
						 

					
					
						 

				

		
			 
		

		
			
		

		

		 

			

					

						Confidential

					

					

						3

				

		

			 

		

 

		

			

		

	
					
						

					
						Accepted and Agreed:

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						/s/ Gerald F. Cox

					
					
						 

					
					
						 

				
	
					
						Gerald F. Cox, M.D., PhD

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						19 July 2016

					
					
						 

					
					
						 

				
	
					
						Date

					
					
						 

					
					
						 

				

		
			 
		

		 

			

					

						Confidential

					

					

						4edit_Ex10_16

		

			Exhibit 10.16

		

		

			 

		

		
			EXECUTION COPY
		

		
			 
		

		
			FIRST AMENDMENT 
		

		
			TO EXCLUSIVE PATENT LICENSE AGREEMENT
		

		
			 
		

		
			MGH Agreement No: A221317
		

		
			 
		

		
			This First Amendment (“First Amendment”) to the Exclusive Patent License Agreement by and between Editas Medicine, Inc. (“Company”) and The General Hospital Corporation d/b/a Massachusetts General Hospital (“Hospital”) dated as of August 29, 2014 (“Agreement”) is made as of the 29th day of June, 2015 (the “First Amendment Effective Date”).  Capitalized terms used in this First Amendment that are not otherwise defined herein shall have the same meanings as such terms are given in the Agreement.  Each reference to a Section herein is a reference to such Section of the Agreement.
		

		
			 
		

		
			WHEREAS, the Parties wish to amend the Agreement to clarify the rights and obligations of the Parties with respect Confidential Information (as defined in Appendix E attached to the Agreement);
		

		
			 
		

		
			NOW THEREFORE, in consideration of the premises and mutual covenants contained in this First Amendment, the Parties agree as follows:
		

		
			 
		

		
			1.         A new Section 12.14 is hereby added to Agreement, to read in its entirety as follows:
		

		
			“12.14 Confidentiality.  
		

		
			(a)       Appendix E attached hereto is incorporated by reference into Agreement.
		

		
			(b)       All reports and other information disclosed by Company to Hospital pursuant to Sections 2.3, 3, 4 and 5, and any information obtained by Hospital pursuant to any audit conducted under Section 5.5, shall be included in the “Confidential Information” of Company (as such term is defined and used in Appendix E).
		

		
			(c)       The terms and conditions of Agreement shall be the “Confidential Information” of each of Company and Hospital.
		

		
			(d)       Notwithstanding anything in Appendix E to the contrary, Company may disclose the Confidential Information of the Hospital (i) to actual and bona fide potential investors, lenders and acquirors/acquirees, merger partners, other financial or commercial partners to the extent necessary in connection with a proposed equity or debt financing of Company, or a proposed acquisition or business combination, or to actual and bona fide potential sublicensees, so long as such recipients are bound in writing to maintain the confidentiality of such information in accordance with the terms of Agreement and/or (ii) to the extent required under the rules or regulations of the U.S. Securities and Exchange Commission, or any similar regulatory agency in any country other than the United States, or of any stock exchange, including Nasdaq; provided that, to the extent 
		

		
			
		

		
			

		 

		

			-1-

		

 

		

		
			practicable, Company promptly notifies Hospital prior to such required disclosure, discloses such information only to the extent so required and cooperates reasonably with Hospital’s efforts to contest or limit the scope of such disclosure.”  
		

		
			2.         Except as expressly amended hereby, the terms and conditions of Agreement shall remain unchanged and in full force and effect.  In the event of any conflict between the terms of this First Amendment and the terms of Agreement, the terms of this First Amendment shall govern.  This First Amendment shall be effective as of the First Amendment Effective Date.  
		

		
			[Signature page follows]
		

		
			
		

		
			

		 

		

			-2-

		

 

		

		
			IN WITNESS WHEREOF, the Parties have caused this First Amendment to be executed by their duly authorized representatives as of the First Amendment Effective Date.
		

		
			 
		

		
			 
		

			
					
						EDITAS MEDICINE, INC.

					
					
						    

					
					
						GENERAL HOSPITAL CORPORATION

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Katrine S. Bosley

					
					
						 

					
					
						By:

					
					
						/s/ Daniel Castro

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Name:

					
					
						Katrine S. Bosley

					
					
						 

					
					
						Name:

					
					
						Daniel Castro

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						Director, Business Strategy

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						And Licensing, Innovation

				
	
					
						Title:

					
					
						President and CEO

					
					
						 

					
					
						Title:

					
					
						Partners HealthCare

				

		
			 
		

		
			 
		

		 

		

			-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]